Where does Astellas Pharma Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Astellas Pharma Inc. ranks #2,418 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Astellas Pharma Inc. hold?

Astellas Pharma Inc. holds 161 US utility patents granted between 2015 and 2025, spanning 18 technology areas.

What is Astellas Pharma Inc.'s Innovation Score?

Astellas Pharma Inc. has an Innovation Score of 48.9 out of 100 (top 16% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Astellas Pharma Inc. focus on?

Astellas Pharma Inc.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 132 patents, ranking #112 of 6,058 assignees active in that subclass. Grants appear in 18 CPC subclasses total.

Is Astellas Pharma Inc.'s patent grant rate increasing or decreasing?

Astellas Pharma Inc.'s recent grant velocity is +0% compared to the prior five-year period (grant years, not application filing dates). The company is maintaining or growing its granted-patent output.

What does claim depth mean for Astellas Pharma Inc.'s patents?

Astellas Pharma Inc.'s patents average 14.5 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Astellas Pharma Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Astellas Pharma Inc.

USPTO PatentsView assignee record - 161 granted patents across 18 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Astellas ranks #2,418 of 49,997 tracked US assignees by granted-patent volume, with 161 patents across 18 technology areas.

#2,418
of 49,997 US assignees by volume: Top 16%
by Innovation Score (48.9/100): 14.5
avg claims per patent: +0%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R2418 · Foreign Corporation #2,418 · 161 grants

GRANTS-MID · TOP-DECILE · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · VEL-FLAT · BOOK-FULL

GRANTS-MID 161 grants
TOP-DECILE #2,418/49,997
PHOTO-FINISH AOl
CPC-FOCUS A61P · 18 areas
INNOV-PAR 48.9/100
CLAIMS-RICH 14.5 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-FLAT +0% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: AOl (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Astellas’s 48.9 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 17.6 pts (36%) Velocity 7.6 pts (16%) Breadth 15.0 pts (31%) Claim depth 8.7 pts (18%)

Qualcomm Incorporated · highest

85
Array BioPharma · near

49
Astellas Pharma · this assignee

49
Huawei Device… · near

49
LifeCell · near

49
Vorbeck Materials · near

49
3D Lighting… · lowest

7

What this shows Astellas's Innovation Score is 48.9/100 (top 16% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Astellas?

Each dot is one of Astellas’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Astellas’s own 14.5 claims/patent is at or below the 17.1 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Astellas vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Astellas's grants concentrate

Astellas Pharma Inc. is a focused PatentsView assignee: 18 CPC subclasses with 82% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2024 (20 grants) versus a trough of 11 in 2021. By volume, Astellas sits between Spin Master Ltd. and HCL Technologies Limited.

Astellas's three-year grant acceleration

From 2019–2021 to 2022–2024, Astellas Pharma Inc. moved from 41 to 47 grants (1.15x the prior three-year total, a multiple, not a CAGR). Among 3,296 tracked assignees with ≥100 grants and ≥20 prior-period grants, that multiple ranks #873. See the growth leaderboard.

Spin Master

162
Sambanova Systems

162
Thomas & Betts In…

162
Aol

161
Elenion

161
Equinix

161
Graham Packaging

161
HCL

161
Astellas Pharma ◀

161

What this shows Astellas holds 161 patents at rank #2,418, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Astellas

By rank, the assignees closest to #2,418 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Astellas's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Astellas, neither rank-band nor same-CPC leaders (those blocks stay above). In A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…), Astellas ranks #112 of 6,058 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (49 here).

Huawei Device (Dongguan) Co., Ltd. 49 LifeCell Corporation 49 Vorbeck Materials Corp. 49 Array BioPharma, Inc. 49

Similar claim depth

Nearest assignees by average claims per patent (14.5 here).

Tyco Electronics Japan G.K. 14.5 avg Conti Temic microelectronic GmbH 14.5 avg Rhode Island Hospital 14.5 avg BD Kiestra B.V. 14.5 avg

Astellas's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

49 Top 16% higher than 84% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Astellas Pharma Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	16	9.9%
2016	18	11.2%
2017	16	9.9%
2018	14	8.7%
2019	12	7.5%
2020	18	11.2%
2021	11	6.8%
2022	12	7.5%
2023	15	9.3%
2024	20	12.4%
2025partial year	9	5.6%

Which technologies does Astellas Pharma Inc. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 132

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 120

C07K - Peptides 62

C07D - Heterocyclic Compounds 56

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 40

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 14

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 13

C12P - Fermentation OR Enzyme-using Processes TO Synthesise A Desired Chemical Compound OR Composition OR TO Separate Optical Isomers From A Racemic Mixture 7

C07C - Acyclic OR Carbocyclic Compounds 4

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 4

A61N - ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy 3

C12Y - Enzymes 3

A01N - Preservation OF Bodies OF Humans OR Animals OR Plants OR Parts Thereof ; Biocides, e.g. AS Disinfectants, AS Pesticides OR AS Herbicides ; Pest Repellants OR ATTRACTANTS; Plant Growth Regulators 2

C30B - Single-crystal Growth ; Unidirectional Solidification OF Eutectic Material OR Unidirectional Demixing OF Eutectoid MATERIAL; Refining BY Zone-melting OF Material ; Production OF A Homogeneous Polycrystalline Material With Defined Structure ; Single Crystals OR Homogeneous Polycrystalline Material WI 1

A01K - Animal HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; Rearing OR Breeding Animals, NOT Otherwise Provided FOR; NEW Breeds OF Animals 1

Top 15 of 18 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Astellas Pharma Inc.'s patent record in context - here's where to go next.

Astellas Pharma Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 82% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #2,418 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Astellas Pharma Inc. against Spin Master Ltd., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 48.9/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.